SKCD in Early Relapsed/Refractory Multiple Myeloma

Multiple myeloma (MM) is a malignant hematologic neoplasm arising from abnormal plasma cells within the bone marrow. Although substantial therapeutic progress has been achieved over the past twenty years, MM remains an incurable disease for the vast majority of patients. When the disease relapses or becomes refractory after 1 to 3 prior lines of therapy (termed early relapsed or refractory multiple myeloma \[RRMM\]), achieving deep and durable remission during early salvage therapy is critical to extending long-term survival. Current guideline-recommended second-line therapies exhibit distinc

Trial Details

NCT ID
NCT07931391
Phase
PHASE2
Sponsor
Beijing Chao Yang Hospital
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • SKCD
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Candidates must satisfy all of the following inclusion criteria to be enrolled in the study:
  • 1\. Age: Age \> 18 years, male or female.
  • 2\. Measurable Disease: Diagnosed with multiple myeloma according to the 2014 IMWG diagnostic criteria, with measurable disease at screening define…
  • Serum M-protein level \> 10 g/L (1.0 g/dL); OR

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →